SynthesisMedicine2025
Association between serum uric acid levels and myasthenia gravis: A meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum uric acid (UA) levels may be involved in the development of myasthenia gravis (MG) by inhibiting oxidative stress, but the relationship remains unclear. This meta-analysis aimed to assess the association between serum UA levels and MG patients.
methodsAccording to the established protocol, researchers searched 9 databases for studies on UA levels in MG patients, assessed using the Newcastle-Ottawa Scale. Heterogeneity was evaluated with the I2 statistic and chi-square test. Publication bias was analyzed using funnel plots and Egger test.
resultsThis meta-analysis included 9 case-control studies from China, with 2112 participants (955 MG patients, 1157 healthy controls). All studies had Newcastle-Ottawa Scale quality scores of 7 or above. Results showed significantly lower serum UA levels in MG patients compared to controls (I2 = 58%, mean difference [MD]: -43.86, 95% confidence interval [CI]: [-54.98, -32.74], P < .00001). Age differences were identified as a source of heterogeneity, confirmed by subgroup analysis. Subgroup analyses showed that in age-comparable groups, MG and healthy controls had lower heterogeneity in UA levels (I2 = 18%, MD: -36.57, 95% CI: [-44.62, -28.50], P < .00001), and in age-disparate groups (I2 = 0%, MD: -73.78, 95% CI: [-94.13, -53.44], P < .00001). Gender analyses showed UA levels in men (I2 = 69%, MD: -60.29, 95% CI: [-81.75, -38.83], P < .00001) and women (I2 = 1%, MD: -29.80, 95% CI: [-38.03, -21.57], P < .00001).
conclusionLower serum levels of UA are associated with an increased risk of MG, although further large-scale, well-controlled studies are needed to confirm the potential clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.